Claramax

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Desloratadine 5mg

Disponibbli minn:

Bayer New Zealand Limited

INN (Isem Internazzjonali):

Desloratadine 5 mg

Dożaġġ:

5 mg

Għamla farmaċewtika:

Film coated tablet

Kompożizzjoni:

Active: Desloratadine 5mg Excipient: Calcium hydrogen phosphate dihydrate Carnauba wax Maize starch Opadry blue 32B10817 Opadry Clear YS-1-19025-A Powdered cellulose Purified talc White beeswax

Unitajiet fil-pakkett:

Blister pack, Aclar/PVC-Al; 3 tablet sample, 3 tablets

Klassi:

Pharmacy only

Tip ta 'preskrizzjoni:

Pharmacy only

Manifatturat minn:

Schering-Plough Company

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, Aclar/PVC-Al; 3 tablet sample - 3 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aclar/PVC-Al; 7 tablet pack - 7 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aclar/PVC-Al; 28 tablet pack - 28 tablets - 24 months from date of manufacture stored at or below 25°C

Data ta 'l-awtorizzazzjoni:

1999-11-24

Karatteristiċi tal-prodott

Medsafe Logo
INFORMATION FOR
HEALTH PROFESSIONALS
Home  |  Consumers  |  Health Professionals  |  Regulatory  |  Other  |  Hot Topics  |  Search
Data Sheet
Claramax
Desloratadine tablets and syrup
NAME OF MEDICINE
CLARAMAX (desloratadine 5 mg) Tablets
CLARAMAX (desloratadine 0.5 mg/mL) Syrup
DESCRIPTION
CLARAMAX tablets contain desloratadine 5 mg and the following inactive ingredients:
Core: calcium hydrogen phosphate, microcrystalline cellulose, maize starch and talc
Coating: Opadry Blue, Opadry Clear, carnauba wax and white beeswax
CLARAMAX Syrup contains desloratadine 0.5 mg/mL and the following inactive ingredients:
Propylene glycol, sorbitol, anhydrous citric acid, sodium citrate, disodium edetate, sucrose, bubble gum
flavour, colour E110, water and sodium benzoate as preservative.
USES
Actions
Desloratadine is a non-sedating long-acting histamine antagonist with potent, selective peripheral H
1
-
receptor antagonist activity. Desloratadine has demonstrated antiallergic, antihistaminic and anti-
inflammatory activities.
Pharmacodynamics
After oral administration, desloratadine selectively blocks peripheral histamine H
1
-receptors because the
drug is effectively excluded from entry to the central nervous system.
In addition to antihistaminic activity, desloratadine has demonstrated antiallergic and anti-inflammatory
In addition to antihistaminic activity, desloratadine has demonstrated antiallergic and anti-inflammatory
activities from numerous in vitro (mainly conducted on cells of human origin) and in vivo studies. These
studies have shown that desloratadine inhibits the broad cascade of events that initiate and propagate
allergic inflammation including:
The release of proinflammatory cytokines including IL-4, IL-6, IL-8, IL-13,
The release of important proinflammatory chemokines such as RANTES (Re